This invention concerns fluorinated 3,4-diaryl-4,5-dihydro-1H-pyrazole-1-carboxamidine derivatives as cannabinoid-CB
1
receptor antagonists, methods for preparing these compounds, novel intermediates useful for the synthesis of said compounds, methods for the preparation of these intermediates, pharmaceutical compositions containing one or more of these dihydropyrazole derivatives as active ingredient, as well as the use of these pharmaceutical compositions for the treatment of obesity and obesity-related cardiovascular disorders, drug addiction, cognition deficits, liver fibrosis and inflammatory disorders. The compounds have the general formula (I)
wherein the symbols have the meanings given in the specification.
本发明涉及
氟化的3,4-二芳基-4,5-二
氢-1H-
吡唑-1-羧
酰胺衍
生物,作为
大麻素CB1受体
拮抗剂,制备这些化合物的方法,用于合成上述化合物的新型
中间体,制备这些
中间体的方法,含有一种或多种这些
二氢吡唑衍
生物作为活性成分的制药组合物,以及利用这些制药组合物治疗肥胖和肥胖相关心血管疾病、药物成瘾、认知缺陷、肝纤维化和炎症性疾病的用途。这些化合物的一般式为(I),其中符号的含义在说明书中给出。